A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502057-33-00

Acronym

TCD17710

Enrollment

Registered

2023-06-15

Start date

2023-10-02

Completion date

2025-05-26

Last updated

2025-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyloid light-chain amyloidosis, Relapsed/refractory multiple myeloma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Belgium, Czechia, Greece, Hungary, Italy, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026